Dermatomyositis - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Dermatomyositis - Pipeline Review, H1 2018’, provides an overview of the Dermatomyositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dermatomyositis

- The report reviews pipeline therapeutics for Dermatomyositis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Dermatomyositis therapeutics and enlists all their major and minor projects

- The report assesses Dermatomyositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Dermatomyositis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dermatomyositis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dermatomyositis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bristol-Myers Squibb Co

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Hope Pharmaceuticals Inc

Idera Pharmaceuticals Inc

Neovacs SA

Novartis AG

Octapharma AG

Pfizer Inc

Bristol-Myers Squibb Co

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Hope Pharmaceuticals Inc

Idera Pharmaceuticals Inc

Neovacs SA

Novartis AG

Octapharma AG

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Dermatomyositis – ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Dermatomyositis – Overview 7

Dermatomyositis – Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Products under Development by Companies 11

Dermatomyositis – Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Dermatomyositis – Companies Involved in Therapeutics Development 20

Bristol-Myers Squibb Co 20

Chugai Pharmaceutical Co Ltd 20

Eli Lilly and Co 21

Hope Pharmaceuticals Inc 21

Idera Pharmaceuticals Inc 21

Neovacs SA 22

Novartis AG 22

Octapharma AG 23

Pfizer Inc 23

Dermatomyositis – Drug Profiles 25

abatacept – Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

baricitinib – Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

bazlitoran sodium – Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

immune globulin (human) – Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

lenabasum – Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

PF-06823859 – Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

siponimod – Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

sodium thiosulfate – Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

tocilizumab – Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

tofacitinib citrate – Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders – Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

VIB-7734 – Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Dermatomyositis – Dormant Projects 111

Dermatomyositis – Product Development Milestones 112

Featured News & Press Releases 112

Apr 26, 2018: Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference 112

Mar 02, 2018: Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference 112

Feb 06, 2018: Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference 112

Nov 27, 2017: Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases 113

Oct 31, 2017: Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases 113

Oct 19, 2017: Corbus Pharmaceuticals Reports Positive Top line Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis 114

Jul 19, 2017: Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFN-alpha Kinoid Clinical Development Program in Dermatomyositis 115

May 17, 2017: FDA Grants Octapharma USA Orphan Drug Designation for Octagam 10% for the Treatment of Dermatomyositis 116

May 11, 2017: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis 116

May 04, 2017: Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis 117

Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference 117

Feb 09, 2017: Neovacs Issued New Broad Patent in China for IFNa Kinoid 118

Nov 29, 2016: Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis 118

Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation 119

Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 120

Appendix 121

Methodology 121

Coverage 121

Secondary Research 121

Primary Research 121

Expert Panel Validation 121

Contact Us 121

Disclaimer 122

List of Tables

List of Tables

Number of Products under Development for Dermatomyositis, H1 2018 8

Number of Products under Development by Companies, H1 2018 10

Products under ...

List of Tables

Number of Products under Development for Dermatomyositis, H1 2018 8

Number of Products under Development by Companies, H1 2018 10

Products under Development by Companies, H1 2018 11

Number of Products by Stage and Target, H1 2018 13

Number of Products by Stage and Mechanism of Action, H1 2018 15

Number of Products by Stage and Route of Administration, H1 2018 17

Number of Products by Stage and Molecule Type, H1 2018 19

Dermatomyositis – Pipeline by Bristol-Myers Squibb Co, H1 2018 20

Dermatomyositis – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018 20

Dermatomyositis – Pipeline by Eli Lilly and Co, H1 2018 21

Dermatomyositis – Pipeline by Hope Pharmaceuticals Inc, H1 2018 21

Dermatomyositis – Pipeline by Idera Pharmaceuticals Inc, H1 2018 22

Dermatomyositis – Pipeline by Neovacs SA, H1 2018 22

Dermatomyositis – Pipeline by Novartis AG, H1 2018 23

Dermatomyositis – Pipeline by Octapharma AG, H1 2018 23

Dermatomyositis – Pipeline by Pfizer Inc, H1 2018 24

Dermatomyositis – Dormant Projects, H1 2018 111

List of Figures

List of Figures

Number of Products under Development for Dermatomyositis, H1 2018 8

Number of Products under Development by Companies, H1 2018 9

Number of ...

List of Figures

Number of Products under Development for Dermatomyositis, H1 2018 8

Number of Products under Development by Companies, H1 2018 9

Number of Products by Top 10 Targets, H1 2018 12

Number of Products by Stage and Top 10 Targets, H1 2018 12

Number of Products by Top 10 Mechanism of Actions, H1 2018 14

Number of Products by Stage and Mechanism of Actions, H1 2018 14

Number of Products by Routes of Administration, H1 2018 16

Number of Products by Stage and Routes of Administration, H1 2018 16

Number of Products by Molecule Types, H1 2018 18

Number of Products by Stage and Molecule Types, H1 2018 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports